(Total Views: 727)
Posted On: 06/04/2022 12:09:27 AM
Post# of 148892
Could this be the pay day we are all waiting for?
This is a Stocktwits post:
ShortsAreDead
Bullish
8m
$CYDY
Back April 20th, I downloaded the accepted abstracts list for the ILC 2022 event in London. Leronlimab NASH's presentation was not yet accepted. However, it is listed when I download the final list today. It is going to be a poster presentation not only a publication.
Link: easl.eu/event/international...
As the screenshot shows, if NASH topline result is junk and shows no efficacy Cytodyn would not even waste the money and time to apply for this event. Dr. Mazen Noureddin would never waste his time especially his reputation fly over to London and make a fool out of himself.
As I have said before, I usually do not pump or make a bold prediction. Given the recent changes within the management and how NASH topline result abstract was accepted, I can confidently say again that we will be handsomely paid off for our patient and commitment.
These are just my opinions! Do your own DD. GLTA!!!
This is a Stocktwits post:
ShortsAreDead
Bullish
8m
$CYDY
Back April 20th, I downloaded the accepted abstracts list for the ILC 2022 event in London. Leronlimab NASH's presentation was not yet accepted. However, it is listed when I download the final list today. It is going to be a poster presentation not only a publication.
Link: easl.eu/event/international...
As the screenshot shows, if NASH topline result is junk and shows no efficacy Cytodyn would not even waste the money and time to apply for this event. Dr. Mazen Noureddin would never waste his time especially his reputation fly over to London and make a fool out of himself.
As I have said before, I usually do not pump or make a bold prediction. Given the recent changes within the management and how NASH topline result abstract was accepted, I can confidently say again that we will be handsomely paid off for our patient and commitment.
These are just my opinions! Do your own DD. GLTA!!!
(6)
(0)Scroll down for more posts ▼
